Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising prostate cancer drug trial halted early

NCT ID NCT04030559

Terminated Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 21, 2026 · Updated 1 time

Summary

This study tested the drug niraparib in men with high-risk prostate cancer that had not spread. The drug targets tumors with specific DNA repair problems. Only 11 men enrolled before the study was stopped early. The goal was to see if the drug could shrink or eliminate tumors before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.

ATM GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CDK12 GENE MUTATION CHEK1 GENE MUTATION CHEK2 GENE MUTATION DNA DAMAGE RESPONSE GENE MUTATION DNA REPAIR GENE MUTATION DNA REPAIR GENE MUTATION FANCA GENE MUTATION FANCD2 GENE MUTATION FANCL GENE MUTATION GEN1 GENE MUTATION NBN GENE MUTATION PROSTATE CARCINOMA RAD51 GENE MUTATION RAD51C GENE MUTATION